We did not apply restrictions on article type
Uses the same batch-linked documentation model, including COA access, Janoshik source-lab records, Testide verification, and LAL screening for supported batches
Semaglutide is the active ingredient in Wegovy, indicated for obesity and Ozempic, for diabetes
If weight loss does not accelerate within 8-12 weeks of adding phentermine, the cardiovascular risk is not justified and phentermine should be discontinued
Tirzepatide is not approved for autoimmune disease treatment, and it should never be used as a substitute for established autoimmune therapies
Some plans are cutting back coverage to GLP-1s in response to costs Coverage for GLP-1 drugs has decreased by 50% since December 2022 as insurers face irresponsible prescription rates for recreational reasons